Common and Rare Hematological Manifestations and Adverse Drug Events during Treatment of Active TB: A State of Art.
adverse events
anemia
hematopoietic system
rare hematologic disorders
tuberculosis
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
09 Jul 2021
09 Jul 2021
Historique:
received:
07
06
2021
revised:
02
07
2021
accepted:
08
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
8
8
2021
Statut:
epublish
Résumé
Tuberculosis (TB) can seriously affect the hematopoietic system, with involvement of both myeloid and lymphoid cell lines as well as plasma components. These hematological changes act as a marker for the diagnosis, prognosis and response to therapy. We searched PubMed, Scopus, Google Scholar, EMBASE, Cochrane Library and WHO websites from 1950 to May 2021 for papers on the interaction between TB and common and rare hematological manifestation. Hematological reactions in patients with TB are possible in both young and old women and men but seem more frequent in the elderly, and they can be predictors of both diagnosis and worse outcome for TB, regardless of whether it is pulmonary, extra pulmonary or miliary. Even anti-TB therapies can cause hematological adverse events, among which some are serious and rare and can compromise the patient's recovery pathway to completing treatment. Hematological screening and follow-up, including complete blood count and coagulation, are always necessary both at the diagnosis of TB and during antitubercular treatment in order to monitor hematological parameters. Short therapy regimens for multidrug-resistant TB (MDR-TB) may also be useful for reducing hematological toxicity, especially in contexts where this cannot be monitored. Close monitoring of drug interactions and hematological adverse events is always recommended.
Sections du résumé
BACKGROUND
BACKGROUND
Tuberculosis (TB) can seriously affect the hematopoietic system, with involvement of both myeloid and lymphoid cell lines as well as plasma components. These hematological changes act as a marker for the diagnosis, prognosis and response to therapy.
METHODS
METHODS
We searched PubMed, Scopus, Google Scholar, EMBASE, Cochrane Library and WHO websites from 1950 to May 2021 for papers on the interaction between TB and common and rare hematological manifestation.
RESULTS
RESULTS
Hematological reactions in patients with TB are possible in both young and old women and men but seem more frequent in the elderly, and they can be predictors of both diagnosis and worse outcome for TB, regardless of whether it is pulmonary, extra pulmonary or miliary. Even anti-TB therapies can cause hematological adverse events, among which some are serious and rare and can compromise the patient's recovery pathway to completing treatment.
CONCLUSION
CONCLUSIONS
Hematological screening and follow-up, including complete blood count and coagulation, are always necessary both at the diagnosis of TB and during antitubercular treatment in order to monitor hematological parameters. Short therapy regimens for multidrug-resistant TB (MDR-TB) may also be useful for reducing hematological toxicity, especially in contexts where this cannot be monitored. Close monitoring of drug interactions and hematological adverse events is always recommended.
Identifiants
pubmed: 34361913
pii: microorganisms9071477
doi: 10.3390/microorganisms9071477
pmc: PMC8304680
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
South Med J. 1990 Jan;83(1):60-3
pubmed: 2405500
Br J Dis Chest. 1970 Jul;64(3):164-8
pubmed: 5476291
Int J Lepr Other Mycobact Dis. 1976 Jul-Sep;44(3):287-93
pubmed: 824210
Int J Mycobacteriol. 2020 Apr-Jun;9(2):205-208
pubmed: 32474545
Rinsho Ketsueki. 2008 Nov;49(11):1566-8
pubmed: 19047790
J Pediatr. 1973 Sep;83(3):502-3
pubmed: 4541998
J Am Med Assoc. 1953 Nov 21;153(12):1094-5
pubmed: 13096346
Thromb Res. 2010 May;125(5):478-80
pubmed: 20137804
J Assoc Physicians India. 2001 Aug;49:788, 790-4
pubmed: 11837465
J R Coll Physicians Edinb. 2018 Jun;48(2):127-129
pubmed: 29992202
Chest. 1982 Jun;81(6):765-6
pubmed: 7075316
Pharmacol Res. 2002 Aug;46(2):191-4
pubmed: 12220960
J Antimicrob Chemother. 1985 Sep;16(3):407-8
pubmed: 4055546
Int J Pharm Pract. 2019 Dec;27(6):575-577
pubmed: 31058394
Pediatr Blood Cancer. 2008 Dec;51(6):821-3
pubmed: 18680155
Chest. 1994 Nov;106(5):1638-9
pubmed: 7956448
Rev Tuberc Pneumol (Paris). 1963 Apr;27:403-20
pubmed: 13929892
J Antimicrob Chemother. 2003 May;51 Suppl 2:ii45-53
pubmed: 12730142
Environ Health Prev Med. 2021 Jan 23;26(1):13
pubmed: 33485299
Ann Clin Microbiol Antimicrob. 2016 Jun 22;15(1):41
pubmed: 27334498
J Pediatr Pharmacol Ther. 2016 Jul-Aug;21(4):353-357
pubmed: 27713676
Antimicrob Agents Chemother. 2002 Aug;46(8):2723-6
pubmed: 12121967
Eur Respir J. 2020 Dec 24;56(6):
pubmed: 32586889
Indian J Pediatr. 2005 Feb;72(2):175-6
pubmed: 15758544
J Clin Pathol. 1987 Jun;40(6):676-9
pubmed: 3611396
Indian J Tuberc. 2019 Apr;66(2):299-307
pubmed: 31151500
Med Clin (Barc). 2001 Jul 7;117(5):197-8
pubmed: 11481089
Br J Clin Pharmacol. 2017 Aug;83(8):1758-1772
pubmed: 28186644
J Allergy Clin Immunol. 2012 Dec;130(6):1413-4
pubmed: 22840850
Rev Iberoam Micol. 2007 Dec 31;24(4):312-6
pubmed: 18095767
Tuberc Respir Dis (Seoul). 2015 Apr;78(2):125-7
pubmed: 25861347
J Clin Pharm Ther. 2019 Feb;44(1):84-90
pubmed: 30243033
Blood. 1967 May;29(5):697-712
pubmed: 6023546
Am Rev Tuberc. 1957 Nov;76(5):862-6
pubmed: 13478840
PLoS One. 2014 Mar 18;9(3):e91229
pubmed: 24642636
Scand J Infect Dis. 2009;41(6-7):480-2
pubmed: 19452349
Case Rep Med. 2012;2012:459140
pubmed: 22567017
Transfusion. 2017 Nov;57(11):2715-2719
pubmed: 28782250
Kekkaku. 2012 Nov;87(11):719-25
pubmed: 23367831
Scand J Rheumatol. 1997;26(6):456-60
pubmed: 9433407
Infect Chemother. 2019 Jun;51(2):142-149
pubmed: 31270993
Pulmonology. 2021 May-Jun;27(3):269-272
pubmed: 32439299
N Engl J Med. 2007 Aug 9;357(6):580-7
pubmed: 17687133
Am Rev Respir Dis. 1964 Mar;89:440-3
pubmed: 14129347
Am J Clin Pathol. 2013 May;139(5):584-6
pubmed: 23596109
BMJ Case Rep. 2018 Oct 7;2018:
pubmed: 30297494
Am J Clin Pathol. 2013 Jun;139(6):713-27
pubmed: 23690113
Am J Med Sci. 2017 Feb;353(2):166-171
pubmed: 28183418
Medicine (Baltimore). 2020 Oct 2;99(40):e22583
pubmed: 33019474
Therapie. 1982 Jul-Aug;37(4):447-50
pubmed: 7135328
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29038274
Thromb Haemost. 2005 Apr;93(4):729-34
pubmed: 15841321
Clin Infect Dis. 2003 Jan 15;36(2):159-68
pubmed: 12522747
Int J Tuberc Lung Dis. 2016 May;20(5):704-5
pubmed: 27084828
J Thromb Haemost. 2009 Jun;7(6):911-8
pubmed: 19344362
Arch Intern Med. 1972 Sep;130(3):388-9
pubmed: 5055697
Eur J Intern Med. 2015 Sep;26(7):e23-4
pubmed: 25912822
Infect Drug Resist. 2020 Sep 28;13:3309-3316
pubmed: 33061478
Lancet. 1996 Sep 7;348(9028):685
pubmed: 8782773
Am J Emerg Med. 2019 Jun;37(6):1195-1196
pubmed: 30340990
Trop Doct. 2019 Apr;49(2):143-144
pubmed: 30541387
J Thromb Thrombolysis. 2020 May;49(4):644-650
pubmed: 31606827
Case Rep Med. 2013;2013:353798
pubmed: 23710189
Am J Kidney Dis. 1998 Jan;31(1):108-15
pubmed: 9428460
Am Rev Respir Dis. 1962 Jan;85:105-9
pubmed: 13913052
BMJ Open. 2019 Apr 2;9(4):e027179
pubmed: 30944140
Eur Respir J. 2015 Jan;45(1):25-9
pubmed: 25552734
Haematologica. 2013 Nov;98(11):e138-40
pubmed: 24186315
Br Med J. 1970 Jul 4;3(5713):24-6
pubmed: 5427483
J Assoc Physicians India. 2010 Apr;58:243-4
pubmed: 21046880
J Thorac Dis. 2015 Dec;7(12):2234-42
pubmed: 26793345
Indian J Pharmacol. 2010 Apr;42(2):108-9
pubmed: 20711377
Eur J Clin Microbiol Infect Dis. 1993 Apr;12(4):303-4
pubmed: 8513823
Can J Med Technol. 1950 Dec;12(4):160-7
pubmed: 24539986
Pharmacotherapy. 2001 Apr;21(4):493-7
pubmed: 11310523
Acta Derm Venereol. 2004;84(1):92-3
pubmed: 15040497
Arch Bronconeumol (Engl Ed). 2018 Nov;54(11):591-592
pubmed: 29804948
BMJ Open. 2019 Nov 12;9(11):e031402
pubmed: 31722945
Case Rep Infect Dis. 2014;2014:865909
pubmed: 24987539
Intern Med. 2015;54(10):1291-5
pubmed: 25986273
Chest. 1970 Apr;57(4):378-81
pubmed: 5434719
Antibiotics (Basel). 2020 Aug 07;9(8):
pubmed: 32784552
Clin Pharmacol Ther. 2003 Dec;74(6):591-2; discussion 592-3
pubmed: 14663461
PLoS One. 2018 Apr 20;13(4):e0195985
pubmed: 29677205
Farm Hosp. 2007 Jul-Aug;31(4):253-4
pubmed: 18052622
Indian J Med Sci. 1973 May;27(5):392-3
pubmed: 4746240
Arch Intern Med. 1962 Aug;110:187-90
pubmed: 14477776
Int J Mycobacteriol. 2020 Apr-Jun;9(2):216-219
pubmed: 32474548
J Thromb Thrombolysis. 2021 Feb;51(2):502-512
pubmed: 32627124
J Med Assoc Thai. 2009 Jun;92 Suppl 3:S69-71
pubmed: 19702070
Rev Med Chil. 1973 Feb;101(2):151-4
pubmed: 4731775
Indian J Chest Dis Allied Sci. 2016 Jul;58(3):189-190
pubmed: 30152654
Eur Respir J. 2015 Nov;46(5):1461-70
pubmed: 26381514
BMJ Case Rep. 2012 Sep 30;2012:
pubmed: 23035171
Acta Med Scand. 1967 Oct;182(4):427-32
pubmed: 5234000
Chest. 2001 Jun;119(6):1961-3
pubmed: 11399734
Microbiol Spectr. 2016 Dec;4(6):
pubmed: 28084210
Blood. 1964 Nov;24:616-23
pubmed: 14236736